City of Hope is known for clinical excellence and their commitment to patient care. This expansion has been driven by patient demand in Southern California and the success that patients have with DigniCap. We are thrilled that more patients will now have access this life-changing treatment as we move even closer to scalp cooling becoming a standard of care.
This partnership with Dignitana enables us to improve the patient experience, Our physicians are committed to providing exceptional cancer care. By being able to offer the DigniCap to patients undergoing chemotherapy, we’ll be helping to diminish the added emotional burden from hair loss.
AON provides a unique model of physician-led community oncology that aligns well with our organizational goals, Physicians know that hair loss is a significant quality of life issue and they want to provide DigniCap for their patients. This master contract expedites the administrative process so that more patients can access this life-changing therapy.
As one of India’s fastest growing healthcare companies, MedPhy Technologies is known for providing scientifically proven, safe, and clinically effective medical technology to the country’s most trusted health facilities. It is a privilege to partner with MedPhy to bring DigniCap to India.
The preservation of dignity is critically important to any patient. DigniCap addresses one of the most devastating side effects of chemotherapy, preserving a patient’s dignity at a very vulnerable time. The integration of scalp cooling into comprehensive cancer care in India will play an especially important role in improving well-being among the country’s at-risk patient populations.
Susan G. Komen remains committed to the fight against breast cancer, taking every step we can toward our mission of saving lives and supporting those affected by breast cancer. We are so grateful for supporters like Dignitana and look forward to seeing the impact our partnership will make.
“As the world’s leading nonprofit breast cancer organization, Susan G. Komen launched a movement that has made a worldwide impact in the fight against breast cancer. We are honored to support Susan G. Komen and the important work they do from the community level up.
DigniCap Delta changes everything about the way scalp cooling is done today. Australia is a very important market for us and, as scalp cooling has become a standard of care for patients here, the Delta device will enable our partner sites to offer this valuable therapy option to more patients and much more efficiently.
Clinicians want to help patients maintain a level of privacy and control that is often lost after diagnosis. Helping cancer care teams address quality of life is an essential component of what we do every single day. Our DigniCap Dignitaries are just one more way we provide patients with a highly personalized level of support and care.
Identity, privacy and confidence became important and very personal concerns when I was diagnosed with cancer and put on a chemotherapy regimen. I’m incredibly honored by this opportunity to help others who I’m sure will have tons of questions, just as I did. To have someone who can help you know what to expect is so important. I can’t wait to connect with other cancer patients looking to keep their hair during chemo.
The technological advances engineered into the new DigniCap Delta bring scalp cooling therapy to a whole new level, This streamlined model offers a new gold standard in patient comfort, flexibility and precision fit and is designed for ease of use and efficiency by clinicians.
As the leading innovator in scalp cooling technology we know first-hand the importance of knowledge, early diagnoses and treatment. We welcome initiatives that highlight the quest for supportive cancer care and enhance quality of life options.
We are pleased that this approval comes at a time when both awareness of and demand for scalp cooling are rapidly increasing. The clearance of Delta now provides a clear pathway for growth in the important U.S. market and beyond. It is the biggest step yet in the evolution of Dignitana and is the result of a tremendous effort from our staff, partner sites, regulatory team and contract manufacturer.
DigniCap Delta changes everything about the way scalp cooling is done today. In the value-based U.S. health care system providers tell us they want to improve the clinical process, reduce nursing intervention and optimize patient outcomes. This new device, developed along with our partner sites, allows them to accomplish all three of these objectives. We are thrilled to offer patients and clinicians this state-of-the-art advancement in cancer care.
Dignitana is moving forward with positive momentum. We are confident that the new system will provide clear benefits to hospitals and patients and we look forward to accelerated growth with the launch of this new system in the first half of 2019.
This is a very important first step in our commitment to bring DigniCap to the Asian market in conjunction with our distribution partner Konica Minolta. As of yet there is no data from a clinical study of scalp cooling with an exclusively Asian population. Beijing Cancer Hospital is a leading cancer treatment facility in Asia and we are eager to work with them in this milestone study.
The results we posted this quarter represent a very important milestone for Dignitana. Quarterly revenue for the company reached 9,022 TSEK. With the organizational restructuring we have implemented, the company is close to reaching a breakeven point in regard to our costs for continuing operations.
As Dignitana now moves into a new chapter, the broad and varied expertise of the proposed slate of Thomas Kelly, Ingrid Atteryd Heiman and Mikael Wahlgren will be a tremendous asset to our continued growth and development.
We hope this expanded FDA clearance will be welcome news for thousands of Americans diagnosed with solid tumors each year.
The new decision by the FDA means that our potential market in the US is more than tripled.
“The CHILL Registry is an incredible platform that will allow us to track progress and connect with physicians around the world to ensure that we can continue to deliver the most effective scalp cooling treatments available.”
“Dignitana is keen to align with support groups in the area to facilitate awareness and access to DigniCap treatments”
Mario Lacouture, MD, Director of the Oncodermatology Program at Memorial Sloan Kettering
William Cronin, Chief Executive Officer of Dignitana, Inc.
We are pleased with the consistent strong growth we are experiencing in the U.S. since FDA clearance nine months ago. The DigniCap system is being included as an integral part of the treatments offered by national leaders in comprehensive breast health services in the U.S. Up to date, forty-seven DigniCap scalp-cooling systems have been ordered for installation by US customers.
We are very excited that DigniCap® is being so well-received in the U.S., and that we’ve been able to quickly and effectively fulfil product requests. From the New York Metropolitan area to communities throughout the midwest, the south, and California, it is clear that DigniCap is filling an important need in quality of life cancer care and medical centers are eagerly promoting its addition to their cancer services.
This FDA clearance means that finally, breast cancer patients in the U.S. will have access to a convenient, safe and scientifically proven option for reducing chemotherapy-induced hair loss.
Working with the professionals at our clinical trial sites has given us a significant head start in learning how best to provide the DigniCap® scalp cooling system here in the U.S.
The time is right to introduce DigniCap® at SABCS to physicians who are eager to provide their patients with an alternative to one of the most widely feared side effects of chemotherapy.
“We feel honored to be nominated and ranked as one of the fastest growing technology companies by Deloitte. We’ve grown during the ranking’s period, and we have fantastic journey in front of us with United States Food and Drug Administration approval pending.”
To have recruited all patients is a milestone for our company and a major step forward in our PMA process.